J.C. Rozendaal

J.C. Rozendaal is a seasoned patent litigator and a director at Sterne, Kessler, Goldstein & Fox, where he also serves as chair of the firm's Trial & Appellate Practice Group. He joined Sterne Kessler in January 2017.

Rozendaal's practice primarily focuses on complex intellectual property litigation in federal courts, with a significant emphasis on pharmaceutical patent litigation, including Hatch-Waxman and biosimilar matters. His case experience spans a broad range of technologies, including pharmaceuticals, aseptic packaging systems, optical disc drives, medical ultrasound, Voice-over-Internet-Protocol (VoIP), LCD flat-panel displays, and streaming video technology. The tracked cases highlight his substantial involvement in pharmaceutical patent disputes, representing both branded and generic companies. He has experience on both the plaintiff (3 cases) and defendant (3 cases) sides of patent litigation, indicating a balanced practice.

Notable cases include representing Biocon Biologics, Inc. in patent litigation against Regeneron Pharmaceuticals, Inc., which resulted in a settlement allowing Biocon to launch its aflibercept biosimilar, Yesafili, in the US by the second half of 2026. He also represented Harmony Biosciences Management Inc. as a plaintiff in an ongoing patent dispute against AET Pharma US Inc. On the defense side, Rozendaal was lead counsel for Sun Pharmaceutical Industries Ltd. in litigation brought by Veloxis Pharmaceuticals Inc., an Abbreviated New Drug Application (ANDA) patent case. Additionally, he was involved in Astellas Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc., a patent infringement action which was dismissed with prejudice following an early settlement. Rozendaal frequently briefs and argues cases before the U.S. Court of Appeals for the Federal Circuit and has represented clients at the U.S. Supreme Court.

Rozendaal is recognized for his work concerning generic pharmaceutical product manufacturers, which includes IPR work. His firm, Sterne Kessler, is highly active in Patent Trial and Appeal Board (PTAB) proceedings, including inter partes reviews (IPRs) and post-grant reviews (PGRs), further indicating his likely involvement in such proceedings as part of his broader patent litigation practice.

He earned his J.D. from The University of Texas School of Law with highest honors, an M.A. from Oxford University, Brasenose College, with first-class honors, and a B.A. from The University of Texas at Austin with highest honors. He is admitted to practice in the District of Columbia, before the U.S. Supreme Court, and multiple U.S. Courts of Appeals and District Courts.